Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias01:16

ECG Interpretation of Arrhythmias I: Sinus Arrhythmias

Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism, and...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of combined nutritional supplementation with biotin, omega-3 polyunsaturated fatty acids and vitamin D in depression: a preclinical study.

Journal of complementary & integrative medicine·2026
Same author

Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.

Diabetes research and clinical practice·2026
Same author

Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.

Frontiers in cellular and infection microbiology·2026
Same author

Behavioral attenuation of marble burying and digging mirrors evoked and non-evoked phenotypes in the endometriosis mouse model.

Scientific reports·2026
Same author

Interleukin-6 as a biomarker of sepsis and its clinical utility in predicting mortality: a prospective observational study.

Journal of infection in developing countries·2025
Same author

Self-Trapping Phenomenon, Multistability and Chaos in Open Anisotropic Dicke Dimer.

Physical review letters·2025
Same journal

Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection.

BMJ case reports·2026
Same journal

<b>Severe hypokalaemia and secretory diarrhoea secondary to a vasoactive intestinal peptide-secreting tumour (VIPoma</b>).

BMJ case reports·2026
Same journal

Intraductal oncocytic papillary neoplasm of the pancreas.

BMJ case reports·2026
Same journal

Post-extubation pneumothorax following bougie-assisted endotracheal tube exchange.

BMJ case reports·2026
Same journal

Cardiac tamponade secondary to hypothyroidism.

BMJ case reports·2026
Same journal

Unmasking a rare contrast reaction: acute non-cardiogenic pulmonary oedema after iohexol injection.

BMJ case reports·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Lithium-induced sinus node dysfunction at therapeutic levels.

Ranjan K Shetty1, G Vivek, Amrita Parida

  • 1Department of Cardiology, Kasturba Medical College, Manipal, Karnataka, India.

BMJ Case Reports
|January 25, 2013
PubMed
Summary
This summary is machine-generated.

Lithium, a mood stabilizer, can cause adverse effects. This case report highlights lithium-induced sinus-node dysfunction, even within therapeutic serum lithium levels, emphasizing careful patient monitoring.

Related Experiment Videos

Last Updated: May 14, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Lithium is a widely prescribed medication for bipolar disorder and other manic conditions.
  • Common side effects include gastrointestinal issues, tremors, and polyuria.
  • Cardiac adverse effects, though less common, can be serious.

Observation:

  • A patient undergoing lithium therapy presented with symptoms suggestive of cardiac dysfunction.
  • Serum lithium levels were monitored and found to be within the standard therapeutic range.

Findings:

  • The patient exhibited sinus-node dysfunction, a condition affecting the heart's natural pacemaker.
  • This dysfunction was directly attributed to lithium treatment, despite therapeutic serum concentrations.

Implications:

  • This case underscores the potential for lithium to cause significant cardiac adverse effects, even at recommended doses.
  • Clinicians should maintain a high index of suspicion for cardiac complications in patients on lithium therapy.
  • Further research may be warranted to elucidate the precise mechanisms of lithium-induced sinus-node dysfunction.